MedTrace Logo

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

NCT06294912 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-01-13

No results posted yet for this study

Summary

The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.

Conditions

Interventions

OTHER

Plasmodium falciparum

Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

DRUG

MK-7602

Capsules to be administered orally.

DRUG

Artemether/lumefantrine

Tablets to be administered orally as definitive antimalarial treatment.

DRUG

Primaquine

Tablets to be administered orally as definitive antimalarial treatment.

DRUG

Artesunate

Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

DRUG

Atovaquone/proguanil

Tablets to be administered orally as definitive antimalarial treatment.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-18
Primary Completion
2025-01-06
Completion
2025-01-06

Countries

  • Australia

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06294912 on ClinicalTrials.gov